<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02243891</url>
  </required_header>
  <id_info>
    <org_study_id>LAAPITUP3</org_study_id>
    <nct_id>NCT02243891</nct_id>
  </id_info>
  <brief_title>AF Ablation With or Without ROX Coupler Study</brief_title>
  <acronym>LAAPITUP3</acronym>
  <official_title>Left Atrial Ablation for Paroxysmal Atrial Fibrillation and Hypertension With Implantable Loop Recorder With or Without ROX Coupler Follow Up Study: The LAAPITUP 3 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neil Sulke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eastbourne General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will test the hypothesis that ablation of paroxysmal atrial fibrillation in&#xD;
      hypertensive subjects is more effective when a ROX coupler is inserted concurrently.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The single blinded, randomised study is planned to commence in October 2014 after obtaining&#xD;
      Research Ethics Committee and NHS Research and Development approval. A target of 20&#xD;
      participants with symptomatic paroxysmal AF will be recruited. All participants will be&#xD;
      blinded and randomised to AF ablation only or AF ablation + ROX coupler implant. All&#xD;
      participants will have right and left heart catheterisation prior to AF ablation +/- ROX&#xD;
      coupler insertion. Participants will be followed up 6 weeks, 3, 6 months and 12 months after&#xD;
      the ablation. The study will take place at Eastbourne District General. The study duration&#xD;
      per patient is 13months. The overall study duration will be 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AF ablation success</measure>
    <time_frame>3 months</time_frame>
    <description>No AF burden detected on implantable loop recorder</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atrial fibrillation ablation only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ROX Coupler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atrial fibrillation ablation with concurrent ROX Coupler insertion</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Atrial fibrillation ablation</intervention_name>
    <description>Percutaneous catheter ablation for Atrial fibrillation.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>ROX Coupler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ROX Coupler insertion</intervention_name>
    <description>The ROX Coupler is a CE-marked device designed to maintain an iliac arteriovenous fistula</description>
    <arm_group_label>ROX Coupler</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic paroxysmal AF suitable for AF ablation.&#xD;
&#xD;
          -  Office Systolic blood pressure ≥ 140 mmHg based on an average of 3 blood pressure&#xD;
             readings&#xD;
&#xD;
          -  Ambulatory Blood Pressure Monitoring (ABPM) daytime average systolic blood pressure&#xD;
             (SBP) ≥ 135 mmHg;&#xD;
&#xD;
          -  Resistant Hypertension: Patients with established hypertension (diagnosed ≥ 12 months&#xD;
             prior to baseline) and is on a guideline based drug regimen at a stable and a fully&#xD;
             tolerated dose, consisting of ≥3 hypertensive medications (including 1 diuretic), or&#xD;
&#xD;
          -  Uncontrolled Hypertension: Patient has drug intolerances to antihypertensive&#xD;
             medications and is unable to take a guideline based drug regimen&#xD;
&#xD;
          -  VO2 peak &gt; 15mls/Kg/min on Cardiopulmonary exercise testing (CPX)&#xD;
&#xD;
          -  Peak RER &gt; 1.0 on Cardiopulmonary exercise testing&#xD;
&#xD;
          -  Age over 18 years old.&#xD;
&#xD;
          -  Informed consent to participate in this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary hypertension amenable to conventional therapy&#xD;
&#xD;
          -  Left ventricular systolic dysfunction with EF &lt; 50%&#xD;
&#xD;
          -  E/E' &gt; 15 on transthoracic echocardiography&#xD;
&#xD;
          -  Uncontrolled diabetes.&#xD;
&#xD;
          -  Body Mass Index &gt; 40 kg/m2&#xD;
&#xD;
          -  Contraindicated for treatment with an arteriovenous anastomosis or interventional&#xD;
             vascular procedure&#xD;
&#xD;
          -  Severe chronic kidney disease as indicated by estimated glomerular filtration rate &lt;&#xD;
             30 mL/min/1.73m2 using the MDRD calculation&#xD;
&#xD;
          -  Renal denervation within the last 6 months&#xD;
&#xD;
          -  Significant peripheral arterial and/or venous disease in the lower limbs (including&#xD;
             unprovoked deep vein thrombosis, significant lower extremity edema and/or venous&#xD;
             insufficiency)&#xD;
&#xD;
          -  Current diagnosis of unstable cardiac disease requiring intervention,or significant&#xD;
             history of serious cardiac comorbidity that may affect patient safety or study&#xD;
             outcomes&#xD;
&#xD;
          -  Current diagnosis of severe cerebrovascular disease or stroke within the past year&#xD;
&#xD;
          -  Female patient who is pregnant, breastfeeding or planning to become pregnant; females&#xD;
             of child-bearing potential must have a negative urine pregnancy test prior to&#xD;
             treatment&#xD;
&#xD;
          -  Any known, unresolved history of drug use or alcohol dependency, lacks the ability to&#xD;
             comprehend or follow instructions, or would be unlikely or unable to comply with study&#xD;
             follow-up requirements&#xD;
&#xD;
          -  Scheduled or planned surgery in the next 6 months that may affect patient safety or&#xD;
             study outcomes&#xD;
&#xD;
          -  Concurrent enrollment in another clinical trial without prior approval of ROX Medical,&#xD;
             Inc.&#xD;
&#xD;
          -  Any serious medical condition that may adversely affect the patient's safety, limit&#xD;
             the subject's ability to participate in the study, comply with follow-up requirements&#xD;
             or impact the scientific integrity of the study&#xD;
&#xD;
          -  Intolerant or allergic to all anti-thrombolytic medications including aspirin&#xD;
&#xD;
          -  Pulmonary arterial hypertension (PAH) defined as mean pulmonary artery pressure (mPAP)&#xD;
             &gt;30 mmHg as measured by right heart catheterization&#xD;
&#xD;
          -  Pulmonary capillary wedge pressure (PCWP) &gt; 15mmHg as measured by right heart&#xD;
             catheterization&#xD;
&#xD;
          -  Pre-existing ILRs or permanent pacemakers that do not allow for continuous monitoring&#xD;
             for AF occurrence.&#xD;
&#xD;
          -  Participation in a conflicting study.&#xD;
&#xD;
          -  Potential participants who are mentally incapacitated and cannot consent or comply&#xD;
             with follow-up.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Other cardiac rhythm disorders.&#xD;
&#xD;
          -  Severe aortic and mitral valve disease.&#xD;
&#xD;
          -  Previous ROX coupler implantation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Sulke, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>East Sussex healthcare NHS trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ragunath Shunmugam, M.B,B.S</last_name>
    <phone>+441323417400</phone>
    <phone_ext>4132</phone_ext>
    <email>r.shunmugam@nhs.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eastbourne District General Hospital</name>
      <address>
        <city>Eastbourne</city>
        <state>East Sussex</state>
        <zip>BN21 2UD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>September 16, 2014</study_first_submitted>
  <study_first_submitted_qc>September 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2014</study_first_posted>
  <last_update_submitted>March 8, 2015</last_update_submitted>
  <last_update_submitted_qc>March 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Eastbourne General Hospital</investigator_affiliation>
    <investigator_full_name>Neil Sulke</investigator_full_name>
    <investigator_title>Consultant Cardiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

